 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...4445464748495051525354...208209» |
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination with Chemotherapy for Organ Preservation in Esophageal Cancer (clinicaltrials.gov) - Mar 10, 2025
P2, N=283, Not yet recruiting, Sponsor: Peking University Cancer Hospital & Institute
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2/3 trial, IO biomarker: A Clinical Study Comparing Chemotherapy Combined with PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients with Positive Lymph Nodes After Surgery: a Multicenter Randomized Controlled Clinical Trial (clinicaltrials.gov) - Mar 10, 2025
P2/3, N=440, Active, not recruiting, Sponsor: Women's Hospital School Of Medicine Zhejiang University
- |||||| SHR-1819 / Jiangsu Hengrui Pharma
Enrollment open: Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis (clinicaltrials.gov) - Mar 10, 2025
P3, N=650, Recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment change: SHR-A1811-Ib/II-205: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (clinicaltrials.gov) - Mar 10, 2025
P2, N=258, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting N=156 --> 258
- | paclitaxel / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Analysis of the efficacy and safety of camrelizumab combined with chemotherapy for cervical cancer treatment. (Pubmed Central) - Mar 10, 2025
No adverse responses of grade 3 or higher were detected. Our analysis showed that the combination of camrelizumab and chemotherapy effectively reduced tumor size and malignancy in cervical cancer treatment, demonstrating robust anti-tumor activity with a favorable safety profile.
- || Clinical, Retrospective data, Journal, Real-world evidence: A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer. (Pubmed Central) - Mar 10, 2025
The most common adverse reaction associated with pyrotinib is diarrhea, which can be well controlled through antidiarrheal treatment. Pyrotinib combined with vinorelbine has similar efficacy to pyrotinib combined with capecitabine and has fewer side effects, and can be used as an alternative to capecitabine.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Mechanism of Atractylenolide ? alleviating pyrotinib-induced diarrhea by regulating AMPK/CFTR pathway through metabolite of gut microbiota. (Pubmed Central) - Mar 10, 2025
This study could provide potential novel traditional Chinese medicine targets for treating diarrhea caused by tyrosine kinase inhibitor drugs, such as pyrotinib. The study emphasizes the role of TCM in minimizing adverse effects during tumor treatment.
- ||| HRS-5965 / Jiangsu Hengrui Pharma
Enrollment open, Trial completion date, Trial primary completion date: A Trial of HRS-5965 Tablets in Primary IgA Nephropathy (clinicaltrials.gov) - Mar 10, 2025
P2, N=115, Recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
The study emphasizes the role of TCM in minimizing adverse effects during tumor treatment. Not yet recruiting --> Recruiting | Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Dec 2024
- | AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Journal: Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies. (Pubmed Central) - Mar 9, 2025
P, P=N/A,
This study provides an overview of camrelizumab use in unselected AEC patients. The real-world effectiveness and safety of camrelizumab are generally consistent with those observed in pivotal trials.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal, Metastases: Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer. (Pubmed Central) - Mar 9, 2025
In the first-, second- and third-line treatment, pyrotinib plus trastuzumab and chemotherapy is effective and safe. Pyrotinib and trastuzumab combined with Albumin-bound paclitaxel may be a potential ideal treatment plan for HER2-positive advanced breast cancer.
- NEOADJUVANT CHEMO-RADIOTHERAPY WITH OR WITHOUT PD-1/PD-L1 INHIBITORS IN LOCALLY ADVANCED RECTAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS (Halls C-E, Lower Level - SDCC) - Mar 8, 2025 - Abstract #DDW2025DDW_7946;
SRCT with PD-1/PD-L1 inhibitors shows better pathological response rates than LRCT. Among the inhibitors, Camrelizumab and Tislelizumab are particularly effective, while Sintilimab and Pembrolizumab show less significant results.
- AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic artery infusion chemotherapy(HAIC) combined with Lenvatinib and Camrelizumab for hepatocellular carcinoma(HCC) with portal vein tumor thrombus(PVTT): a prospective longitudinal real-world study (Poster Area) - Mar 8, 2025 - Abstract #EASL2025EASL_1784;
- | oxaliplatin / Generic mfg., AiTan (rivoceranib) / HLB Bio Group
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy. (Pubmed Central) - Mar 7, 2025
P2
A prospective clinical trial (NCT04195828) demonstrated that a neoadjuvant regimen of apatinib plus ICB and chemotherapy was effective in patients with desert-type GC. Collectively, these findings identify potential drug targets for immune desert-type GC driven by ?-catenin signaling.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Clinical efficacy of pyrotinib combined with chemotherapy for neoadjuvant treatment in HER2-positive breast cancer: a single-center study. (Pubmed Central) - Mar 7, 2025
Diarrhea was the most common adverse event, occurring in 92.3% of patients, with 46.2% experiencing grade 3 or higher diarrhea. No severe adverse events or treatment-related fatalities were reported.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Aidixi (disitamab vedotin) / Pfizer
Journal: Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report. (Pubmed Central) - Mar 7, 2025
This case study suggests that the anti-Her-2 regimen involving Disitamab Vedotin and Pyrotinib may offer a potential salvage treatment option for patients with Her-2-amplified mCRC patients. However, further validation in larger cohorts is necessary in future studies.
- | Journal: Research Progress of M6A Methylation Modification in Immunotherapy of Colorectal Cancer. (Pubmed Central) - Mar 7, 2025
Furthermore, probable challenges in PARPi application and drug resistance mechanisms have also been discussed. Despite these challenges, further development of new PARP1 inhibitors appears promising as a valuable approach to cancer treatment.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2/3 trial: Total Neoadjuvant Therapy Combined with Adebrelimab in Locally Advanced Resectable ESCC (clinicaltrials.gov) - Mar 6, 2025
P2/3, N=474, Not yet recruiting, Sponsor: YIN LI
- |||||||||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
New P3 trial: A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis (clinicaltrials.gov) - Mar 6, 2025
P3, N=380, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Mar 5, 2025
P2, N=54, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Despite these challenges, further development of new PARP1 inhibitors appears promising as a valuable approach to cancer treatment. Not yet recruiting --> Recruiting
- | plinabulin (BPI 2358) / BeyondSpring
Trial completion date, Trial termination, Trial primary completion date: Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (clinicaltrials.gov) - Mar 5, 2025
P1/2, N=19, Terminated, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Jun 2025 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Feb 2025; PI requested.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC (clinicaltrials.gov) - Mar 5, 2025
P2, N=164, Not yet recruiting, Sponsor: Zhigang Li
- |||||| SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment open: A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Mar 5, 2025
P3, N=402, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Trial completion date: Jun 2025 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Feb 2025; PI requested. Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment open, Trial completion date, Trial primary completion date: Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma (clinicaltrials.gov) - Mar 5, 2025
P1/2, N=50, Recruiting, Sponsor: Jun Guo
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
- |||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1/2 trial: SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov) - Mar 5, 2025
P1/2, N=100, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Journal: Hetrombopag treatment for immune thrombocytopenia in pregnancy refractory to corticosteroids and intravenous immunoglobulin: a case report. (Pubmed Central) - Mar 5, 2025
Herein, we report a case of a 31-year-old pregnant woman with recurrent and refractory ITP who was safely and effectively treated with hetrombopag, with no influence on the infant's platelet count. This case explores a new treatment option for the management of recurrent and refractory ITP in pregnancy.
- | SHR-2010 / Jiangsu Hengrui Pharma
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy (clinicaltrials.gov) - Mar 5, 2025
P2, N=53, Terminated, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
This case explores a new treatment option for the management of recurrent and refractory ITP in pregnancy. N=76 --> 53 | Trial completion date: Apr 2026 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Jan 2025; Based on the adjustment of the R & D strategy, the sponsor decides to terminate the research.
- | AiTan (rivoceranib) / HLB Bio Group, Lysodren (mitotane) / Perrigo Company
Enrollment open: Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma (clinicaltrials.gov) - Mar 4, 2025
P2, N=28, Recruiting, Sponsor: West China Hospital
N=76 --> 53 | Trial completion date: Apr 2026 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Jan 2025; Based on the adjustment of the R & D strategy, the sponsor decides to terminate the research. Not yet recruiting --> Recruiting
- | Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Reimbursement, Retrospective data, US reimbursement, Journal, Real-world evidence: Impact of the national health insurance coverage policy on mecapegfilgrastim utilization for chemoradiotherapy-induced neutropenia in cancer patients in China: a retrospective real-world analysis. (Pubmed Central) - Mar 4, 2025
The NHIC policy significantly increased mecapegfilgrastim utilization, enabling more cancer patients to access this medication and effectively benefiting them. To address persistent inequities, the government should consider introducing additional measures, such as increasing the insurance reimbursement cap and separating the cost of expensive innovative anticancer medicines from hospital medical insurance budgets.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment status: Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC (clinicaltrials.gov) - Mar 4, 2025
P2, N=208, Recruiting, Sponsor: The First Affiliated Hospital of Xiamen University
To address persistent inequities, the government should consider introducing additional measures, such as increasing the insurance reimbursement cap and separating the cost of expensive innovative anticancer medicines from hospital medical insurance budgets. Enrolling by invitation --> Recruiting
- || oxaliplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, capecitabine / Generic mfg.
P2 data, Journal, Metastases: Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma. (Pubmed Central) - Mar 3, 2025
P=N/A
No grades 4-5 TRAEs were observed. Perioperative camrelizumab combined with XELOX showed promising pathological response with an acceptable safety profile in patients with resectable locally advanced G/GEJ adenocarcinoma.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Pyrotinib-assisted whole brain radiotherapy alleviates HER2-positive advanced breast cancer and brain metastases: a prospective study in patients. (Pubmed Central) - Mar 3, 2025
Although some instances of adverse events, such as vomiting and reduced white blood cells and neutrophil counts, were evident, these adverse events were grades 1-3. WBRT combined with pyrotinib exhibited exceptional tolerability, showing long iPFS in patients with HER2+ advanced BC and BM.
- || SHR-1916 / Jiangsu Hengrui Pharma
PK/PD data, Journal: SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy. (Pubmed Central) - Mar 3, 2025
SHR-1916 exhibited excellent cellular selectivity, anti-tumor efficacies, and improved pharmacokinetics. It has the potential to serve as a novel immunotherapeutic agent designed to enhance IL-2's immune-stimulating activities and promote its tolerability while reducing the immunoregulatory function of Treg cells.
- || AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Clinical protocol, P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Efficacy and safety of S-1 plus oxaliplatin combined with apatinib and camrelizumab as neoadjuvant therapy for patients with locally advanced gastric or gastroesophageal junction adenocarcinoma: a protocol for a single-arm phase II trial. (Pubmed Central) - Mar 3, 2025
P2
Recent studies suggest that combining chemotherapy, targeted agents, and immune checkpoint inhibitors can enhance the antitumor immune response. This phase II clinical trial seeks to assess the safety and efficacy of the SOXAC regimen as neoadjuvant therapy for patients with locally advanced resectable gastric or GEJ adenocarcinoma, while also exploring the correlation between biomarkers and efficacy.Trial Registration Chinese Clinical Trial Registry (ChiCTR): ChiCTR2200062285 ( https://www.chictr.org.cn/ ).
- || ribupatide injection (HRS9531 injection) / Kailera Therapeutics
New P1 trial: Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects (clinicaltrials.gov) - Mar 3, 2025
P1, N=7, Not yet recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Xpovio (selinexor) / Karyopharm
New trial: Second-line Immunotherapy for ES-SCLC (clinicaltrials.gov) - Mar 3, 2025
P=N/A, N=30, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change, Trial completion date, Trial primary completion date: Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma (clinicaltrials.gov) - Mar 3, 2025
P2, N=60, Recruiting, Sponsor: Peking University Cancer Hospital & Institute
This phase II clinical trial seeks to assess the safety and efficacy of the SOXAC regimen as neoadjuvant therapy for patients with locally advanced resectable gastric or GEJ adenocarcinoma, while also exploring the correlation between biomarkers and efficacy.Trial Registration Chinese Clinical Trial Registry (ChiCTR): ChiCTR2200062285 ( https://www.chictr.org.cn/ ). N=40 --> 60 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: Trastuzumab rezetecan, a new antibody-drug conjugate in HER2-mutated NSCLC. (Pubmed Central) - Mar 1, 2025
N=40 --> 60 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 No abstract available
- || M9466 / EMD Serono
Trial initiation date: Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) (clinicaltrials.gov) - Feb 27, 2025
P1, N=54, Not yet recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
No abstract available Initiation date: Jan 2025 --> Jul 2025
- || Review, Journal: Quintessence of currently approved and upcoming treatments for dry eye disease. (Pubmed Central) - Feb 27, 2025
Initiation date: Jan 2025 --> Jul 2025 Currently, the US Food and Drug Administration (FDA)-approved medical treatments for treatment of DED include cyclosporine formulations (RESTASIS
- | albumin-bound paclitaxel / Generic mfg.
Trial completion date, Trial primary completion date: Albumin-Bound Paclitaxel Combined with Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC (clinicaltrials.gov) - Feb 27, 2025
P2, N=128, Recruiting, Sponsor: The First Affiliated Hospital of Bengbu Medical University
Currently, the US Food and Drug Administration (FDA)-approved medical treatments for treatment of DED include cyclosporine formulations (RESTASIS Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jan 2025 --> Sep 2025
- |||| SHR-1826 / Jiangsu Hengrui Pharma
Enrollment open: A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (clinicaltrials.gov) - Feb 27, 2025
P1/2, N=876, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jan 2025 --> Sep 2025 Not yet recruiting --> Recruiting
- || Clinical, Retrospective data, Review, Journal: Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis. (Pubmed Central) - Feb 27, 2025
300?mg of canagliflozin was the best option among the included interventions considering favourable glucose control and WL. Some novel SGLT2is (eg, henagliflozin) exhibited promising efficacy and safety profiles, but more research is needed to validate the findings.
- | Journal: Drugs for dry eye disease. (Pubmed Central) - Feb 27, 2025
Some novel SGLT2is (eg, henagliflozin) exhibited promising efficacy and safety profiles, but more research is needed to validate the findings. No abstract available
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date: Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Feb 27, 2025
P2, N=25, Recruiting, Sponsor: Fudan University
No abstract available Trial completion date: May 2024 --> Dec 2026 | Trial primary completion date: May 2024 --> Dec 2025
- | Jiataile (sacituzumab tirumotecan) / Merck (MSD), AiRuiKa (camrelizumab) / Elevar Therapeutics, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: SHIFT-001: HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer (clinicaltrials.gov) - Feb 27, 2025
P2, N=120, Not yet recruiting, Sponsor: Fudan University
- |||| HRS-5965 / Jiangsu Hengrui Pharma
Enrollment closed: HRS-5965-301: A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy (clinicaltrials.gov) - Feb 26, 2025
P3, N=76, Active, not recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Trial completion date: May 2024 --> Dec 2026 | Trial primary completion date: May 2024 --> Dec 2025 Recruiting --> Active, not recruiting
- |||| M9466 / EMD Serono
Trial suspension: M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (clinicaltrials.gov) - Feb 26, 2025
P1, N=54, Suspended, Sponsor: EMD Serono Research & Development Institute, Inc.
Recruiting --> Active, not recruiting Recruiting --> Suspended
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical body regions () - Feb 26, 2025 - Abstract #AAD2025AAD_3373;
P3
Recruiting --> Suspended Ivarmacitinib treatment provides rapid and continuous improvement in patients with moderate-to-severe AD in different anatomical body regions.
- vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial () - Feb 26, 2025 - Abstract #AAD2025AAD_3314;
P3
Ivarmacitinib treatment provides rapid and continuous improvement in patients with moderate-to-severe AD in different anatomical body regions. Interrupted vunakizumab treatment reduced the clinical response and quality of life in patients with moderate-to-severe plaque psoriasis.
- vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
Impact of vunakizumab on metabolic parameters and body mass index in moderate-to-severe plaque psoriasis patients with or without comorbidities: a post-hoc analysis of a phase III trial () - Feb 26, 2025 - Abstract #AAD2025AAD_3295;
P3
Interrupted vunakizumab treatment reduced the clinical response and quality of life in patients with moderate-to-severe plaque psoriasis. Vunakizumab did not affect impact metabolic parameters and BMI in patients with moderate-to-severe plaque psoriasis, regardless of comorbidity status.